

SWIXX COMPLETES ELEVEN ADDITIONAL BD DEALS

SWIXX ANNOUNCEMENT NO. 35

February 5th, 2021

Swixx BioPharma SA of Baar, Switzerland announced today that it had signed eighteen deals for new territories and / or products over the past year.

Baar, Switzerland, February 5th, 2021: Swixx S.A. revealed that in addition to the seven deals already announced in the course of 2020 (Alk Abello W. Balkans, Amryt CE, Norgine CE, Sarepta 3 countries,, UPSA/Taisho Russia , Vifor Slovakia and Y-mAbs CE & Russia) it had completed an additional eleven other acquisition, licensing, territory extension or new agency commercialization contracts over the last year:

1. With **Advanz Pharma**[™] to represent Vasaprostan[™] (alprostadil), a medicine indicated for peripheral arterial occlusive disease, for Romania;
2. With **Alcon**[™], extending Swixx's existing relationship with Alcon Surgical in Serbia to include also both Bosnia-Herzegovina and Slovenia;
3. With **Apogepha**[™] in a licensing deal for the urological medicine Detrunorm[™] / Mictonorm[™] (propiverine hydrochloride) for several countries in the West Balkans;
4. With **ASA Pharma**[™] in a licensing deal for Bisopirin[™], bisoprolol-aspirin cardiovascular combination capsules for Bosnia, Croatia, Kosovo, Macedonia, Montenegro and Serbia;
5. With **Bristol-Myers Squibb**[™] and **Celgene**[™] to represent the Celgene portfolio in the Baltic states (Estonia, Latvia and Lithuania), Bulgaria, Croatia, Romania, Slovakia and Slovenia as well as the non-EU W. Balkan countries of Bosnia, Macedonia, Montenegro and Serbia;
6. With **Delta Medical**[™] whereby Swixx acquired Delta's Russia subsidiary and operations, taking over thereby approximately \$17M in sales and an established organization with 85 employees, representing companies such as Biogaia[™], Compeed[™], Hisamitsu[™], Mentholatum[™], Schoenen[™] and Thornton[™];
7. With **General Electric**[™], extending Swixx's existing agreement to represent GE's contrast imaging medicines for Bosnia, Macedonia, Montenegro and Serbia to also cover Croatia, Lithuania and Slovenia;
8. With **Laboratoires Juvise Pharmaceuticals**[™] for the territory of the three Baltic states (Estonia, Latvia and Lithuania) and the West Balkans (ex-Yugo countries plus Albania) to represent the oncological products Casodex[™] (bicalutamide) and Arimidex[™] (anastrozole);
9. With **Merz**[™] for the territory of the three Baltic states (Estonia, Latvia and Lithuania) to represent both its aesthetics portfolio (Belotero and Radiesse) as well as several promising therapeutics including Xeomin[™] (incobotulinumtoxin A) and Merz Spezial;

10. With **Secura Bio™** to represent Farydak® (panobinostat capsules) a medicine indicated for the treatment of multiple myeloma for the territory of CEE plus Russia;
11. With **Vifor Pharma™**, expanding Swixx's original deal to represent Ferrinject™ (ferric carboxymaltose, an injectable iron solution) for Slovakia to include also the Czech Republic and Poland.

"I am very pleased with the continuing strong deal flow we are experiencing here at Swixx," commented Swixx CEO Jean-Michel Lespinnasse. "In particular, we're gratified to see tangible evidence that several of our existing clients continue to broaden their relationships with us – with companies like Alcon, Alexion, BMS-Celgene, GE, Norgine, UPSA/Taisho and Vifor granting to Swixx additional territories or products in 2020. I'm also delighted that Advanz, Apogepha, ASA, Juvise, Merz and Secura Bio have all done us the honour of being chosen to represent their excellent medicines.

"As we go into the new year of 2021," continued Lespinnasse, "I would also like to take this opportunity to recognize the signal contribution that Ivan Pertot, our Regional Director of BD, has made to the length, and depth, of the 2020 Swixx BD deal list. The many and varied deals achieved over the last year could not have been consummated without Ivan and his team's persistence, enthusiasm, hard work and steady, expert hands."

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With 550 employees and net sales exceeding 230M Euros in 2020, Swixx is now the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

Note on Unsubscribing from Swixx Announcement Mailing List: In accordance with the European Union's GDPR (General Data Protection Regulation) provisos, should you wish to unsubscribe / opt out of our mailing list, please send to Maja.Boskovic@swixxbiopharma.com a one-line message "Please unsubscribe me."